HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Congestive heart failure stage C — Clinical Guidelines

Overview

Congestive heart failure (HF) is a complex clinical syndrome resulting from structural or functional cardiac abnormalities that impair the heart's ability to fill with or eject blood 3. Stage C HF, as defined by the American Heart Association/American College of Cardiology (AHA/ACC) guidelines, encompasses symptomatic heart failure 1 2.

Diagnosis

No specific diagnostic criteria or recommended tests for Stage C HF were detailed in the provided abstracts.

Management

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are recommended for patients with heart failure with reduced ejection fraction (HFrEF) 1 2.

SGLT2 inhibitors are also considered for patients with heart failure with mildly reduced and preserved ejection fraction 1 2.

Optimal blood pressure control is a performance measure for patients with heart failure with preserved ejection fraction (HFpEF) 1 2.

Guideline-directed medical therapy (GDMT) should be used in hospitalized patients 1 2.

Therapy optimization is a key domain for HF management 3.

Key Recommendations

The use of sodium-glucose cotransporter-2 inhibitors is recommended for patients with heart failure with reduced ejection fraction 1 2. (Evidence: Strong)

Optimal blood pressure control is recommended for patients with heart failure with preserved ejection fraction 1 2. (Evidence: Strong)

Guideline-directed medical therapy should be utilized in hospitalized patients with heart failure 1 2. (Evidence: Strong)

References

1 Kittleson MM, Breathett K, Ziaeian B, Aguilar D, Blumer V, Bozkurt B et al.. 2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures. Journal of the American College of Cardiology 2024. link 2 Kittleson MM, Breathett K, Ziaeian B, Aguilar D, Blumer V, Bozkurt B et al.. 2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures. Circulation. Cardiovascular quality and outcomes 2024. link 3 Aktaa S, Polovina M, Rosano G, Abdin A, Anguita M, Lainscak M et al.. European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. European journal of heart failure 2022. link

Congestive heart failure stage C

Overview

Diagnosis

Management

Key Recommendations

References

Original source